Ottowa, Canada Clinical Trials

A listing of Ottowa, Canada clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 118 clinical trials
Pragmatic Randomised Trial of High Or Standard PHosphAte Targets in End-stage Kidney Disease (PHOSPHATE)

During end-stage kidney disease, clinical guidelines suggest reducing elevated phosphate levels in the blood. However, the effect of lowering blood phosphate levels on important patient-centred outcomes has never been tested. This trial will evaluate whether compared to high levels, lowering blood phosphate levels would reduce death or major events due …

dialysis
blood phosphate
renal disease
nephropathy
renal failure
The Ottawa Hospital
 (2.3 away) Contact site
  • 91 views
  • 19 Sep, 2021
  • +54 other locations
Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG

The primary objective of this study is to evaluate the effectiveness (prevention of thromboembolic events) and safety (major bleeding) of adding oral anticoagulation (OAC) to background antiplatelet therapy in patients who develop new-onset post-operative atrial fibrillation (POAF) after isolated coronary artery bypass graft (CABG) surgery. All patients with a qualifying …

clopidogrel
atrial fibrillation
anticoagulants
edoxaban
rivaroxaban
University of Ottawa Heart Institute
 (2.2 away) Contact site
  • 112 views
  • 19 Sep, 2021
  • +79 other locations
Tezepelumab COPD Exacerbation Study

A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 2a Study to Explore the Efficacy and Safety of Tezepelumab in Adults with Moderate to Very Severe Chronic Obstructive Pulmonary Disease (COPD)

severe chronic obstructive pulmonary disease
ct scan
copd exacerbation
bronchodilator
Research Site
 (3.4 away) Contact site
  • 130 views
  • 12 Sep, 2021
  • +107 other locations
A Study of Mirvetuximab Soravtansine vs. Investigator's Choice of Chemotherapy in Platinum-Resistant Advanced High-Grade Epithelial Ovarian Primary Peritoneal or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression

This Phase 3 study is designed to compare the efficacy and safety of mirvetuximab soravtansine vs. investigator's choice chemotherapy in patients with platinum-resistant high-grade epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer, whose tumors express a high-level of FR. Patients will be, in the opinion of the Investigator, appropriate …

cytotoxic chemotherapy
epithelial ovarian cancer
antineoplastic
cancer antigen 125
mirvetuximab soravtansine
The Ottawa Hospital General Campus
 (2.7 away) Contact site
  • 88 views
  • 10 Sep, 2021
  • +156 other locations
Study of Durvalumab Given With Chemotherapy Durvalumab in Combination With Tremelimumab Given With Chemotherapy or Chemotherapy in Patients With Unresectable Urothelial Cancer

This is a randomized, open-label, controlled, multi-center, global Phase III study to determine the efficacy and safety of combining durvalumab tremelimumab with standard of care (SoC) chemotherapy (cisplatin + gemcitabine or carboplatin + gemcitabine doublet) followed by durvalumab monotherapy versus SoC alone as first-line chemotherapy in patients with histologically or …

Research Site
 (2.7 away) Contact site
  • 202 views
  • 12 Sep, 2021
  • +286 other locations
Melanoma Margins Trial-II: 1cm v 2cm Wide Surgical Excision Margins for AJCC Stage II Primary Cutaneous Melanoma

Patients with a primary invasive melanoma are recommended to undergo excision of the primary lesion with a wide margin. There is evidence that less radical margins of excision may be just as safe. This is a randomised controlled trial of 1 cm versus 2 cm margin of excision of the …

Ottawa Hospital Research Institute
 (2.7 away) Contact site
  • 7 views
  • 15 Sep, 2021
  • +38 other locations
Dose-ranging Study of Oral PHA-022121 for Acute Treatment of Angioedema Attacks in Patients With Hereditary Angioedema

This study evaluates the efficacy of orally administered PHA-022121 for the acute treatment of attacks in patients with hereditary angioedema (HAE). Eligible subjects are randomized to one of three single doses of PHA-022121 and placebo. The study will compare symptom relief (skin pain, skin swelling, abdominal pain) during HAE attacks …

angioedema
Study site
 (0.0 away) Contact site
  • 0 views
  • 19 Sep, 2021
  • +26 other locations
Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin Cancer

To estimate the clinical benefit of cemiplimab monotherapy versus cemiplimab in combination with RP1 for patients with locally advanced or metastatic CSCC, as assessed by overall response rate (ORR) and complete response rate (CRR) according to blinded independent review.

cancer
cemiplimab
skin cancer
Ottawa Hospital Research Institute
 (2.7 away) Contact site
  • 2 views
  • 12 Sep, 2021
  • +51 other locations
A Study to Evaluate the Safety Pharmacokinetics and Pharmacodynamics of ABBV-181 (Budigalimab) in Adult Participants With Human Immunodeficiency Virus (HIV)-1

This study will be conducted in two stages and will test the safety/tolerability, pharmacokinetics (how the body handles study drug) and pharmacodynamics (effects on the immune system and the virus) of the study drug ABBV-181 in Human immunodeficiency virus (HIV)-1 infected participants undergoing Antiretroviral therapy (ART) interruption.

antiretroviral therapy
HIV Vaccine
body mass index
immunodeficiency
drug test
The Ottawa Hospital /ID# 218083
 (2.7 away) Contact site
  • 149 views
  • 19 Sep, 2021
  • +35 other locations
Study to Assess the Efficacy and Safety of Brolucizumab 6mg Compared to Aflibercept 2 mg in a Treat-to-control Regimen (TALON)

The study is a 64-week randomized, double-masked, multi-center, active-controlled, two-arm study in patients with nAMD (neovascular age related macular degeneration) who have not previously received anti-VEGF (vascular endothelial growth factor) treatment. Patients who consent will undergo screening assessments to evaluate their eligibility based on the inclusion and exclusion criteria.

diabetic retinopathy
retinal pigment
fluorescein angiography
detachment
edema
Novartis Investigative Site
 (2.5 away) Contact site
  • 30 views
  • 18 Sep, 2021
  • +135 other locations